Activating KRAS mutations (G12V or G12D), which occur in nearly a third of epithelial tumors and in nearly 90% of pancreatic cancers, are considered the major driver of consecutive Akt activation in PDAC tissues [4, 6]. The gene discussed is AKT1; the disease is pancreatic neoplasm.